Latest Novaremed News & Updates
See the latest news and media coverage for Novaremed. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage biopharmaceutical company developing non-opioid pain therapies
novaremed.com- Headquarters
- Basel, Switzerland
- Founded year
- 2017
- Company type
- Private company
- Number of employees
- 5–10
Latest news about Novaremed
Company announcements
-
Novaremed completes patient visits in Phase 2b trial
The NIH-funded trial evaluates nispomeben for chronic pain in diabetic peripheral neuropathy. Topline results expected November 2025.
-
Novaremed completes enrollment in Phase 2b study of NRD.E1
The NIH-sponsored trial enrolled 127 patients for non-opioid treatment of diabetic peripheral neuropathy pain. Topline data expected in Q4 2025.
-
Novaremed announces publication of MP-101 pharmacological profile
MP-101, in Phase 2 for preventing chemotherapy-induced peripheral neuropathy, shows superior potency in animal models of pain, cognition, and depression.
-
Novaremed enters license agreement with NeuroFront for NRD.E1
NeuroFront gains option for exclusive rights in Greater China and Singapore. Novaremed receives over USD 130 million in fees, milestones, and royalties.
Media coverage
-
Novaremed Announces Completion of All Patient Visits in NIH-Funded Phase 2b Trial of Non-Opioid Nispomeben for Treating Chronic Pain Associated with Diabetic Peripheral Neuropathy - BioSpace
Basel, Switzerland, 2 September 2025 – Novaremed AG, a privately held clinical-stage biopharmaceutical company, announces completion of the last patient last visit (LPLV) in the...
-
Novaremed Announces Completion of All Patient Visits in NIH-Funded Phase 2b Trial of Non-Opioid Nispomeben for Treating Chronic Pain Associated with Diabetic Peripheral Neuropathy
Last patient last visit (LPLV) was reached for the 127 adult and elderly patients enrolled into the 12-week placebo-controlled trial with nispomeben (NRD.E1) Topline results...
-
Novaremed signs an exclusive option and license agreement with NeuroFront for the non-opioid neuropathic pain treatment, NRD.E1, for Greater China and Singapore
Novaremed AG and NeuroFront Therapeutics (Hong Kong) Limited have jointly announced the signing of an exclusive collaboration and commercialization agreement for...
-
Novaremed AG: The non-opioid lead compound NRD.E1 from Novaremed is being tested in a Phase-2 study of the NIH-HEAL Initiative for the treatment of chronic pain
Novaremed AG, a biopharma private company active in the field of clinical research, announces a study in collaboration with the National Institutes of Health (NIH), in which...
Track Novaremed and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Novaremed competitors & trending companies
Browse news for competitors to Novaremed and other trending companies.
Pila Pharma
Sironax
Aperture Therapeutics
Attentive
Klaviyo
Twilio
Insider One
Zeta Global
Iterable
Braze
Optimove
Bluecore
BlueConic
Amperity
Wero
BLIK
EPI
Swish
Affirm
Brite Payments
TCS
Overview Energy
Adfin
Ineffable Intelligence
Mechanize
Hexatronic
Alimak Group
Lindab Group
NYAB
Noon Energy
Nordan AI
Mips
Vexlum
Asker Healthcare Group